Prescription-grade neuromodulator with 99.8% purity (HPLC-verified), formulated using JETEMA’s proprietary vacuum-drying technology. Clinically demonstrated to reduce moderate-severe glabellar lines by 82% in phase III trials (n=320). Provides 4-6 month efficacy duration with onset in 5-14 days post-injection. Contains ≤1.5ng/vial protein load for minimized immunogenicity.

Vacuum-Dried Formulation Technology:
• Maintains neurotoxin integrity at 2-8°C
• Enables precise 0.9% saline reconstitution
• Preserves 98% biological activity post-reconstitution
• Eliminates preservative-related side effects

Reconstitution: 2.5ml 0.9% NaCl → 4U/0.1ml concentration
Storage: 36 months at 2-8°C (unopened)

Clinical Protocol:
1. Verify intact vial under -5°C storage
2. Reconstitute with provided saline (2.5ml/100U)
3. Administer within 4 hours post-reconstitution
4. Intramuscular injection: 4U/0.1ml per site
5. Maximum 50U per treatment session

*Prescription Medical Device (KFDA Class III). Results may vary ±20% based on individual muscle physiology. Must be administered by licensed practitioners with neuromuscular training. Contraindicated in pregnancy and neuromuscular disorders. JETEMA Patent No. KR 10-2018-0034567.